Latest Content

FDA approves Ziihera combinations for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma, expanding treatment options.

Dr. Matthew Carr explains how CAR T-cell therapy works, who may be eligible and how doctors decide when to treat or monitor cancer.

A medical oncologist at UC San Diego Health on choosing between surgery and radiation, and why precision oncology changes what patients should ask first.

After years of writing about my own cancer, I sat down to write my 94-year-old mother's obituary and learned how differently the two forms hit.

Nicole Echols discusses Lung Cancer Initiative, reducing lung cancer stigma, biomarker testing, early detection and support for patients and caregivers.

Dr. Jia Luo explains how chemotherapy, targeted therapy and immunotherapy work for lung cancer, plus tips for managing treatment side effects.

Jill May, RN, BSN, OCN, of Allina Health Cancer Institute, guided a liver cancer patient and his caregiver wife through three years of treatment, setbacks and ultimately hospice care with unwavering devotion.

Long-term survivorship in small cell lung cancer was not expected 20 years ago. A radiation oncologist explains what that shift means for patients today.

Janet Fuller, DNP, RN, OCN, of Vanderbilt University Medical Center, helped two young breast cancer patients form a support group that now guides dozens of women through diagnosis and treatment.

Three years after ringing the bell for lymphoma, the cancer came back in my brain. Choosing hospice care was the hardest decision I have ever had to make.

Long-term follow-up of a trial found patients with recurrent prostate cancer lived longer after receiving the pTVG-HP vaccine than GM-CSF alone.

ASCO updated its guideline to recommend broader first-line HER2-targeted treatment options, with immunotherapy for eligible patients with PD-L1 expression of 1% or higher.

Cancer drugs sit in a protected class under Medicare Part D, but plans can still deny coverage. A researcher from Vanderbilt found that many of those denials do not hold up under outside review.